Despite weight gain, quitting smoking associated with reduced risk of cardiovascular diseaseWednesday, March 13, 2013
Among adults without diabetes, quitting smoking, compared with continuing smoking, was associated with a lower risk of cardiovascular disease despite subsequent weight gain, according to a study appearing in the March 13 issue of JAMA.
"Cigarette smoking is the leading cause of preventable mortality in the United States and a major risk factor for cardiovascular disease (CVD). Smoking cessation substantially reduces the risks of CVD; however, quitting smoking is associated with a small number of adverse health consequences, weight gain being one of smokers' major concerns," according to background information in the article. The average postcessation weight gain varies between 6.6 lbs. and 13.2 lbs. in North America, happens within 6 months after smoking cessation, and persists over time. Obesity is also a risk factor for CVD. Weight gain following smoking cessation therefore might lessen the benefits of quitting smoking on CVD outcomes. In addition, among people with type 2 diabetes, weight gain following smoking cessation has potential to be of greater concern because it is a risk factor for poor diabetes control and increased risk of illness and death. "The effect on CVD of potential weight gain following smoking cessation is not well understood," the authors write.
Carole Clair, M.D., M.Sc., of the University of Lausanne, Switzerland, and colleagues conducted a study to assess the association between 4-year weight gain following smoking cessation and CVD event rate among adults with and without diabetes. The study included data from the Framingham Offspring Study collected from 1984 through 2011. At each 4-year examination, self-reported smoking status was assessed and categorized as smoker, recent quitter (? 4 years), long-term quitter (>4 years), and nonsmoker. Models were used to estimate the association between quitting smoking and 6-year CVD events and to test whether 4-year change in weight following smoking cessation modified the association between smoking cessation and CVD events. The primary outcome measure was the incidence over 6 years of total CVD events, comprising coronary heart disease, cerebrovascular events, peripheral artery disease, and congestive heart failure.
Weight gain occurred over 4 years in participants without and with diabetes. Among participants without diabetes, recent quitters gained significantly more weight (median [midpoint], 5.9 lbs.) than long-term quitters (1.9 lbs.), smokers (1.9 lbs.), and nonsmokers (3 lbs.). Among patients with diabetes, recent quitters also gained significantly more weight (7.9 lbs.) than smokers (1.9 lbs.), long-term quitters (0.0 lbs., and nonsmokers (1.1 lbs.).
After an average follow-up of 25 years, 631 CVD events occurred among 3,251 participants. The researchers found that among participants without diabetes, the age- and sex-adjusted CVD incidence rates were lower for nonsmokers, recent quitters, and long-term quitters, compared with smokers.
After adjustment for CVD risk factors, compared with smokers, recent quitters had a 53 percent lower risk for CVD and long-term quitters had a 54 percent lower risk for CVD; these associations had only a minimal change after further adjustment for weight change. "Among participants with diabetes, there were similar point estimates that did not reach statistical significance," the authors write.
The researchers observed similar benefits associated with smoking cessation for total CVD and for fatal and non-fatal coronary heart disease, with the cessation benefits not offset by weight gain.
"In conclusion, among adults without diabetes, quitting smoking was associated with a lower risk of CVD compared with continuing smoking. There were qualitatively similar lower risks among participants with diabetes that did not reach statistical significance, possibly because of limited study power. Weight gain that occurred following smoking cessation was not associated with a reduction in the benefits of quitting smoking on CVD risk among adults without diabetes. This supports a net cardiovascular benefit of smoking cessation, despite subsequent weight gain," the authors write.
(JAMA. 2013;309(10):1014-1021; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
There will also be a digital news release available for this study, including the JAMA Report video, embedded and downloadable video, audio files, text, documents, and related links. This content will be available at 3 p.m. CT Tuesday, March 12 at this link.
Editorial: Should Clinicians Encourage Smoking Cessation for Every Patient Who Smokes?
In an accompanying editorial, Michael C. Fiore, M.D., M.P.H., M.B.A., and Timothy B. Baker, Ph.D., of the University of Wisconsin School of Medicine and Public Health, Madison, suggest ways in which the findings of this study can be used by physicians.
"First, data from the study by Clair et al can be used to reassure patients concerned about the health effects of cessation-related weight gain. About 50 percent of female smokers and about 25 percent of male smokers are 'weight concerned,' which may discourage quit attempts and quitting success. Although such reassurance may not assuage concerns about the effects of weight gain on appearance, it may nevertheless be helpful. Furthermore, even though no treatments have been shown to reliably prevent cessation-related weight gain, exercise regimens may be beneficial, and use of nicotine replacement medications can suppress weight gain during their use. Second, physicians should use this information to reinforce their commitment to provide or arrange evidence based treatment for all of their patients who smoke."
(JAMA. 2013;309(10):1032-1033; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: This Editorial was supported by grants from the National Cancer Institute and National Heart, Lung, and Blood Institute. Dr. Fiore reported institutional support from Pfizer for a phase 4 study of varenicline. Dr. Baker reported no disclosures.
The JAMA Network Journals: http://www.jamamedia.org
Thanks to The JAMA Network Journals for this article.
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
This press release has been viewed 39 time(s).